To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016

Những quyển sách tương tự

• To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016
  Bằng: Thomas Christian Kühler, et al.
  Được phát hành: (2019-11-01)
• Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice
  Bằng: Rodier, Céline, et al.
  Được phát hành: (2020)
• The Qualitative Value of Facilitated Regulatory Pathways in Europe, USA, and Japan: Benefits, Barriers to Utilization, and Suggested Solutions
  Bằng: Bujar, Magdalena, et al.
  Được phát hành: (2021)
• FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines
  Bằng: Liberti, Lawrence, et al.
  Được phát hành: (2017)
• A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
  Bằng: Allen, Nicola, et al.
  Được phát hành: (2017)